About Proto-oncogene Wnt-1
Proto-oncogene Wnt-1 (WNT1) is a protein
from Homo sapiens identified by UniProt accession
P04628, 370 residues long.
MolForge cross-references it against 0 known binders and
499 disease associations.
Target properties
| Protein name | Proto-oncogene Wnt-1 |
|---|
| UniProt accession | P04628 |
|---|
| Gene | WNT1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 370 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (499)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.68
- osteogenesis imperfecta · score 0.67
- osteoporosis · score 0.61
- postmenopausal osteoporosis · score 0.55
- bone quantitative ultrasound measurement · score 0.54
- velocity of sound measurement · score 0.43
- genetic disorder · score 0.41
- osteogenesis imperfecta type 3 · score 0.40
- osteogenesis imperfecta type 4 · score 0.37
- sitting height measurement · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P04628-F1 | alphafold | PREDICTED | 85.88 | — |
Amino-acid sequence (370 residues)
MGLWALLPGW VSATLLLALA ALPAALAANS SGRWWGIVNV ASSTNLLTDS KSLQLVLEPS LQLLSRKQRR LIRQNPGILH SVSGGLQSAV RECKWQFRNR RWNCPTAPGP HLFGKIVNRG CRETAFIFAI TSAGVTHSVA RSCSEGSIES CTCDYRRRGP GGPDWHWGGC SDNIDFGRLF GREFVDSGEK GRDLRFLMNL HNNEAGRTTV FSEMRQECKC HGMSGSCTVR TCWMRLPTLR AVGDVLRDRF DGASRVLYGN RGSNRASRAE LLRLEPEDPA HKPPSPHDLV YFEKSPNFCT YSGRLGTAGT AGRACNSSSP ALDGCELLCC GRGHRTRTQR VTERCNCTFH WCCHVSCRNC THTRVLHECL
Explore Proto-oncogene Wnt-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets